Europese Unie - Deens - EMA (European Medicines Agency)

laboratorios hipra, s.a. - rekombinant verotoksin 2e af e. coli - inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) escherichia + clostridium, immunologicals for suidae - svin - aktiv immunisering af smågrise fra 2 dage gammel for at forhindre, at reducere dødelighed og kliniske tegn på ødem sygdomme (forårsaget af verotoksin 2e produceret af e. coli) og for at reducere tabet af daglig vægtforøgelse i efterbehandlingstiden i lyset af infektioner med verotoxin 2e-producerende e. coli indtil slagtning fra 164 dage.

Europese Unie - Deens - EMA (European Medicines Agency)

zoetis belgium sa - modificeret levende svine respiratorisk og reproduktiv syndrom virus - immunologicals for suidae, live viral vaccines - svin - til aktiv immunisering af klinisk raske svin fra 1 dag af alder i en porcine respiratory og reproduktiv syndrom (prrs) - virus forurenet miljøet, at reducere viraemia og nasal kaste forårsaget af infektion med europæisk stammer af prrs-virus (genotype 1). fedtsvin: desuden blev vaccination af seronegative 1-dages gamle grise påvist for signifikant at reducere lungelæsioner mod udfordring indgivet efter 26 uger efter vaccination. vaccination af seronegative 2 uger gamle smågrise blev påvist, at reducere lunge læsioner og mundtlige kaste imod udfordringen administreres på 28 dage, og på 16 uger efter vaccination. gylte og søer: ud, før graviditet vaccination af klinisk raske gylte og søer, enten seropositive eller seronegative, blev påvist, at reducere transplacental infektion forårsaget af prrs-virus i løbet af tredje trimester af graviditeten, og for at mindske den dermed forbundne negative indvirkning på den reproduktive ydeevne (reduktion af forekomst af dødfødsler, grisling viraemia ved fødslen og ved fravænning, af lunge læsioner og viral load i lungerne i smågrise til fravænning).

Europese Unie - Deens - EMA (European Medicines Agency)

virbac s.a. - tulathromycin - antibakterielle midler til systemisk brug - cattle; pigs; sheep - cattle: treatment and metaphylaxis of bovine respiratory disease (brd) associated with mannheimia haemolytica, pasteurella multocida, histophilus somni and mycoplasma bovis susceptible to tulathromycin. tilstedeværelsen af ​​sygdommen i besætningen bør etableres inden metafylaktisk behandling. treatment of infectious bovine keratoconjunctivitis (ibk) associated with moraxella bovis susceptible to tulathromycin. pigs: treatment and metaphylaxis of swine respiratory disease (srd) associated with actinobacillus pleuropneumoniae, pasteurella multocida, mycoplasma hyopneumoniae, haemophilus parasuis and bordetella bronchiseptica susceptible to tulathromycin. tilstedeværelsen af ​​sygdommen i besætningen bør etableres inden metafylaktisk behandling. the product should only be used if pigs are expected to develop the disease within 2–3 days. får: behandling af de tidlige stadier af infektiøs pododermatitis (fodrot) forbundet med virulent dichelobacter nodosus, der kræver systemisk behandling.

Europese Unie - Deens - EMA (European Medicines Agency)

ceva santé animale - tulathromycin - antibakterielle midler til systemisk brug - cattle; pigs; sheep - cattle: treatment and metaphylaxis of bovine respiratory disease (brd) associated with mannheimia haemolytica, pasteurella multocida, histophilus somni and mycoplasma bovis susceptible to tulathromycin. tilstedeværelsen af ​​sygdommen i besætningen bør etableres inden metafylaktisk behandling. treatment of infectious bovine keratoconjunctivitis (ibk) associated with moraxella bovis susceptible to tulathromycin. pigs: treatment and metaphylaxis of swine respiratory disease (srd) associated with actinobacillus pleuropneumoniae, pasteurella multocida, mycoplasma hyopneumoniae, haemophilus parasuis and bordetella bronchiseptica susceptible to tulathromycin. tilstedeværelsen af ​​sygdommen i besætningen bør etableres inden metafylaktisk behandling. the product should only be used if pigs are expected to develop the disease within 2–3 days. får: behandling af de tidlige stadier af infektiøs pododermatitis (fodrot) forbundet med virulent dichelobacter nodosus, der kræver systemisk behandling.

Europese Unie - Deens - EMA (European Medicines Agency)

ceva-phylaxia co. ltd. - live recombinant fowlpox virus expressing the membrane fusion protein and the encapsidation protein of avian infectious laryngotracheitis virus (rfp-lt) and avian encephalomyelitis virus, strain calnek 1143 (ae) - immunologicals for aves, live viral vaccines, domestic fowl - kylling - for active immunisation of chickens of 8 to 13 weeks of age in order to reduce the skin lesions due to fowlpox, to reduce the clinical signs and tracheal lesions due to avian infectious laryngotracheitis and to prevent egg production losses due to avian encephalomyelitis.

Europese Unie - Deens - EMA (European Medicines Agency)

vetoquinol - tulathromycin - antibakterielle midler til systemisk brug - cattle; pigs; sheep - cattle: treatment and metaphylaxis of bovine respiratory disease (brd) associated with mannheimia haemolytica, pasteurella multocida, histophilus somni and mycoplasma bovis susceptible to tulathromycin. tilstedeværelsen af ​​sygdommen i besætningen bør etableres inden metafylaktisk behandling. treatment of infectious bovine keratoconjunctivitis (ibk) associated with moraxella bovis susceptible to tulathromycin. pigs: treatment and metaphylaxis of swine respiratory disease (srd) associated with actinobacillus pleuropneumoniae, pasteurella multocida, mycoplasma hyopneumoniae, haemophilus parasuis and bordetella bronchiseptica susceptible to tulathromycin. tilstedeværelsen af ​​sygdommen i besætningen bør etableres inden metafylaktisk behandling. the product should only be used if pigs are expected to develop the disease within 2–3 days. får: behandling af de tidlige stadier af infektiøs pododermatitis (fodrot) forbundet med virulent dichelobacter nodosus, der kræver systemisk behandling.

Europese Unie - Deens - EMA (European Medicines Agency)

elanco gmbh - tulathromycin - antibakterielle midler til systemisk brug - cattle; pigs; sheep - cattle: treatment and metaphylaxis of bovine respiratory disease (brd) associated with mannheimia haemolytica, pasteurella multocida, histophilus somni and mycoplasma bovis susceptible to tulathromycin. tilstedeværelsen af ​​sygdommen i besætningen bør etableres inden metafylaktisk behandling. treatment of infectious bovine keratoconjunctivitis (ibk) associated with moraxella bovis susceptible to tulathromycin. pigs: treatment and metaphylaxis of swine respiratory disease (srd) associated with actinobacillus pleuropneumoniae, pasteurella multocida, mycoplasma hyopneumoniae, haemophilus parasuis and bordetella bronchiseptica susceptible to tulathromycin. tilstedeværelsen af ​​sygdommen i besætningen bør etableres inden metafylaktisk behandling. the product should only be used if pigs are expected to develop the disease within 2–3 days. får: behandling af de tidlige stadier af infektiøs pododermatitis (fodrot) forbundet med virulent dichelobacter nodosus, der kræver systemisk behandling.

Europese Unie - Deens - EMA (European Medicines Agency)

vmd n.v. - tulathromycin - antibacterials for systemic use, macrolides - cattle; pigs; sheep - cattle: treatment and metaphylaxis of bovine respiratory disease (brd) associated with mannheimia haemolytica, pasteurella multocida, histophilus somni and mycoplasma bovis susceptible to tulathromycin. tilstedeværelsen af ​​sygdommen i besætningen bør etableres inden metafylaktisk behandling. treatment of infectious bovine keratoconjunctivitis (ibk) associated with moraxella bovis susceptible to tulathromycin. pigs: treatment and metaphylaxis of swine respiratory disease (srd) associated with actinobacillus pleuropneumoniae, pasteurella multocida, mycoplasma hyopneumoniae, haemophilus parasuis and bordetella bronchiseptica susceptible to tulathromycin. tilstedeværelsen af ​​sygdommen i besætningen bør etableres inden metafylaktisk behandling. the product should only be used if pigs are expected to develop the disease within 2–3 days. får: behandling af de tidlige stadier af infektiøs pododermatitis (fodrot) forbundet med virulent dichelobacter nodosus, der kræver systemisk behandling.

Europese Unie - Deens - EMA (European Medicines Agency)

dechra regulatory b.v. - tulathromycin - antibakterielle midler til systemisk brug - cattle; pigs; sheep - cattle: treatment and metaphylaxis of bovine respiratory disease (brd) associated with mannheimia haemolytica, pasteurella multocida, histophilus somni and mycoplasma bovis susceptible to tulathromycin. tilstedeværelsen af ​​sygdommen i besætningen bør etableres inden metafylaktisk behandling. treatment of infectious bovine keratoconjunctivitis (ibk) associated with moraxella bovis susceptible to tulathromycin. pigs: treatment and metaphylaxis of swine respiratory disease (srd) associated with actinobacillus pleuropneumoniae, pasteurella multocida, mycoplasma hyopneumoniae, haemophilus parasuis and bordetella bronchiseptica susceptible to tulathromycin. tilstedeværelsen af ​​sygdommen i besætningen bør etableres inden metafylaktisk behandling. the product should only be used if pigs are expected to develop the disease within 2–3 days. får: behandling af de tidlige stadier af infektiøs pododermatitis (fodrot) forbundet med virulent dichelobacter nodosus, der kræver systemisk behandling.

Europese Unie - Deens - EMA (European Medicines Agency)

laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - svin - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.